MA40770A - Dérivés d'imidazoles pentacyclic fusionnés - Google Patents

Dérivés d'imidazoles pentacyclic fusionnés

Info

Publication number
MA40770A
MA40770A MA040770A MA40770A MA40770A MA 40770 A MA40770 A MA 40770A MA 040770 A MA040770 A MA 040770A MA 40770 A MA40770 A MA 40770A MA 40770 A MA40770 A MA 40770A
Authority
MA
Morocco
Prior art keywords
imidazoles
merged
pentacyclic
derivatives
pentacyclic derivatives
Prior art date
Application number
MA040770A
Other languages
English (en)
Other versions
MA40770B1 (fr
Inventor
Daniel Christopher Brookings
Mark Daniel Calmiano
Haro Garcia Teresa De
Michael Deligny
Yves Evrard
Bruno Filoche-Romme
Yann Foricher
Jag Paul Heer
Martin Clive Hutchings
Sophie Jadot
James Andrew Johnson
Jean Keyaerts
Coss Malcolm Mac
Joanna Rachel Quincey
Laurent Schio
Matthew Duncan Selby
Michael Alan Shaw
Dominique Louis Léon Swinnen
Mengyang Xuan
Zhaoning Zhu
Original Assignee
Sanofi Sa
UCB Biopharma SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa, UCB Biopharma SRL filed Critical Sanofi Sa
Publication of MA40770A publication Critical patent/MA40770A/fr
Publication of MA40770B1 publication Critical patent/MA40770B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/12—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
    • C07D493/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
MA40770A 2014-10-03 2015-10-02 Dérivés d'imidazoles pentacyclic fusionnés MA40770B1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP14290299 2014-10-03
EP15162641 2015-04-07
EP15171036 2015-06-08
PCT/EP2015/072868 WO2016050975A1 (fr) 2014-10-03 2015-10-02 Dérivés d'imidazole pentacycliques fusionnés

Publications (2)

Publication Number Publication Date
MA40770A true MA40770A (fr) 2021-03-24
MA40770B1 MA40770B1 (fr) 2021-11-30

Family

ID=54238452

Family Applications (1)

Application Number Title Priority Date Filing Date
MA40770A MA40770B1 (fr) 2014-10-03 2015-10-02 Dérivés d'imidazoles pentacyclic fusionnés

Country Status (36)

Country Link
US (3) US10202405B2 (fr)
EP (1) EP3201196B1 (fr)
JP (1) JP6629847B2 (fr)
KR (1) KR102442235B1 (fr)
CN (1) CN107108672B (fr)
AP (1) AP2017009809A0 (fr)
AU (1) AU2015326798B2 (fr)
BR (1) BR112017006669B1 (fr)
CA (1) CA2962826C (fr)
CL (1) CL2017000787A1 (fr)
CO (1) CO2017003331A2 (fr)
CR (1) CR20170167A (fr)
DK (1) DK3201196T3 (fr)
EA (1) EA032839B1 (fr)
EC (1) ECSP17027306A (fr)
ES (1) ES2885432T3 (fr)
GT (1) GT201700044A (fr)
HR (1) HRP20211605T1 (fr)
HU (1) HUE056133T2 (fr)
IL (1) IL251147B (fr)
LT (1) LT3201196T (fr)
MA (1) MA40770B1 (fr)
MX (1) MX2017004201A (fr)
MY (1) MY181019A (fr)
PE (1) PE20170693A1 (fr)
PH (1) PH12017500414A1 (fr)
PL (1) PL3201196T3 (fr)
RS (1) RS62423B1 (fr)
SG (1) SG11201701796XA (fr)
SI (1) SI3201196T1 (fr)
TN (1) TN2017000083A1 (fr)
TW (1) TWI719949B (fr)
UA (1) UA120764C2 (fr)
UY (1) UY36341A (fr)
WO (1) WO2016050975A1 (fr)
ZA (1) ZA201701946B (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA40770B1 (fr) * 2014-10-03 2021-11-30 Sanofi Sa Dérivés d'imidazoles pentacyclic fusionnés
UY36628A (es) 2015-04-17 2016-11-30 Abbvie Inc Indazolonas como moduladores de la señalización de tnf
TW201710257A (zh) 2015-04-17 2017-03-16 艾伯維有限公司 Ｔｎｆ信號傳遞之三環調節劑
EP3294726A1 (fr) 2015-04-17 2018-03-21 AbbVie Inc. Indazolones utilisées en tant que modulateurs de la signalisation du tnf
GB201510758D0 (en) 2015-06-18 2015-08-05 Ucb Biopharma Sprl Novel TNFa structure for use in therapy
CN109195969B (zh) * 2016-04-01 2021-12-21 Ucb生物制药私人有限公司 作为tnf活性调节剂的稠合五环咪唑衍生物
WO2017167995A1 (fr) 2016-04-01 2017-10-05 Ucb Biopharma Sprl Dérivés d'imidazole hexacycliques condensés utilisés en tant que modulateurs de l'activité du tnf
JP6968090B2 (ja) * 2016-04-01 2021-11-17 ユーシービー バイオファルマ エスアールエル Ｔｎｆ活性のモジュレーターとしての縮合五環式イミダゾール誘導体
CN109219608B (zh) 2016-04-01 2021-12-21 Ucb生物制药私人有限公司 作为tnf活性调节剂的稠合五环咪唑衍生物
GB201620948D0 (en) 2016-12-09 2017-01-25 Ucb Biopharma Sprl Therapeutic agents
GB201621907D0 (en) 2016-12-21 2017-02-01 Ucb Biopharma Sprl And Sanofi Antibody epitope
CN110461842A (zh) * 2017-03-15 2019-11-15 Ucb生物制药私人有限公司 作为tnf活性调节剂的稠合五环咪唑衍生物
TWI801378B (zh) * 2017-04-25 2023-05-11 比利時商Ｕｃｂ生物製藥公司 作為tnf活性調節劑之稠合五環咪唑衍生物
CA3117344A1 (fr) * 2018-10-24 2020-04-30 UCB Biopharma SRL Derives d'imidazole pentacycliques fusionnes utilises en tant que modulateurs de l'activite du tnf
CN113683505A (zh) * 2021-09-29 2021-11-23 厦门大华本安化工安全研究院有限公司 一种含氧代环丁基的羧酸酯类化合物的制备方法
WO2024112796A1 (fr) * 2022-11-23 2024-05-30 Forward Therapeutics, Inc. MODULATEURS DE L'ACTIVITÉ DU TNF-α

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0449649A3 (en) 1990-03-30 1992-09-02 Arizona Board Of Regents, Arizona State University Antineoplastic quinones and methods of using same
FR2832711B1 (fr) 2001-11-26 2004-01-30 Warner Lambert Co Derives de triazolo [4,3-a] pyrido [2,3-d] pyrimidin-5-ones, compositions les contenant, procede de preparation et utilisation
CA2517281A1 (fr) 2003-03-10 2004-10-14 Pfizer Inc. Composes a base d'esters de sulfate/phosphate et compositions pharmaceutiques inhibant l'activite de nima interagissant avec des proteines (pin1)
DE102008030206A1 (de) 2008-06-25 2009-12-31 Bayer Schering Pharma Aktiengesellschaft 3-Cyanoalky- und 3-Hydroxyalkyl-Indole und ihre Verwendung
AR088728A1 (es) 2011-03-25 2014-07-02 Bristol Myers Squibb Co Moduladores de lxr como prodroga de imidazol
ES2576298T3 (es) 2011-06-20 2016-07-06 Vertex Pharmaceuticals Incorporated Ésteres de fosfato de inhibidores de girasa y topoisomerasa
EP2858983B1 (fr) * 2012-06-11 2018-04-18 UCB Biopharma SPRL Benzimidazoles modulant le tnf-alpha
US9309243B2 (en) * 2012-07-13 2016-04-12 Ucb Biopharma Sprl Imidazopyridine derivatives as modulators of TNF activity
GB201212513D0 (en) * 2012-07-13 2012-08-29 Ucb Pharma Sa Therapeutic agents
AP2016009156A0 (en) 2013-10-25 2016-04-30 Novartis Ag Ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors
GB201321728D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321729D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
RS57476B9 (sr) 2014-04-15 2021-10-29 Vertex Pharma Farmaceutske kompozicije za lečenje bolesti posredovanih transmembranskim regulatorom provodljivosti cistične fibroze
MA40770B1 (fr) * 2014-10-03 2021-11-30 Sanofi Sa Dérivés d'imidazoles pentacyclic fusionnés

Also Published As

Publication number Publication date
BR112017006669A2 (pt) 2017-12-26
LT3201196T (lt) 2021-09-27
PL3201196T3 (pl) 2022-01-03
US10906919B2 (en) 2021-02-02
MY181019A (en) 2020-12-16
ECSP17027306A (es) 2017-05-31
CA2962826A1 (fr) 2016-04-07
TW201629067A (zh) 2016-08-16
HUE056133T2 (hu) 2022-01-28
CN107108672B (zh) 2019-11-08
AU2015326798B2 (en) 2020-01-02
EA201790734A1 (ru) 2017-09-29
IL251147A0 (en) 2017-04-30
KR20170068503A (ko) 2017-06-19
BR112017006669B1 (pt) 2023-04-18
US20190367535A1 (en) 2019-12-05
NZ730256A (en) 2021-05-28
WO2016050975A1 (fr) 2016-04-07
US20210155637A1 (en) 2021-05-27
TN2017000083A1 (en) 2018-07-04
GT201700044A (es) 2019-09-09
CA2962826C (fr) 2023-08-08
EA032839B1 (ru) 2019-07-31
SG11201701796XA (en) 2017-04-27
US10202405B2 (en) 2019-02-12
DK3201196T3 (da) 2021-09-06
JP2017531648A (ja) 2017-10-26
EP3201196A1 (fr) 2017-08-09
AP2017009809A0 (en) 2017-03-31
SI3201196T1 (sl) 2021-12-31
CR20170167A (es) 2017-08-10
CL2017000787A1 (es) 2017-11-24
AU2015326798A1 (en) 2017-04-06
UY36341A (es) 2016-04-29
US20170305932A1 (en) 2017-10-26
PH12017500414B1 (en) 2017-07-17
PH12017500414A1 (en) 2017-07-17
MX2017004201A (es) 2017-05-30
JP6629847B2 (ja) 2020-01-15
UA120764C2 (uk) 2020-02-10
US11912721B2 (en) 2024-02-27
HRP20211605T1 (hr) 2022-01-21
CN107108672A (zh) 2017-08-29
ES2885432T3 (es) 2021-12-13
MA40770B1 (fr) 2021-11-30
KR102442235B1 (ko) 2022-09-08
CO2017003331A2 (es) 2017-09-29
EP3201196B1 (fr) 2021-07-28
PE20170693A1 (es) 2017-06-13
ZA201701946B (en) 2018-07-25
TWI719949B (zh) 2021-03-01
IL251147B (en) 2020-05-31
RS62423B1 (sr) 2021-10-29

Similar Documents

Publication Publication Date Title
MA40770A (fr) Dérivés d'imidazoles pentacyclic fusionnés
DK3319956T3 (da) Substituerede oxopyridinderivater
BR112017020349A2 (pt) derivados heterobicíclicos microbicidas
DK3286183T3 (da) Isoxazolylsubstituerede benzimidazoler
MA54254A (fr) Dérivés de benzodiazépine cytotoxique
DK3253762T3 (da) 9h-pyrrolo-dipyridinderivater.
DK3231803T3 (da) Dihydroindolizinonderivat
DK3131898T3 (da) Fluoroalkylfluorenderivativer
DK3680243T3 (da) Pentacyklisk forbindelse
MA49708A (fr) Dérivés de dihétérocycle liés à cycloalkyle
DK3645513T3 (da) Benzazepinderivater
DK3484889T3 (da) Ethynylderivater
DK3331600T3 (da) Kateter
DK3642202T3 (da) Dihydro-pyrrolo-pyridin-derivater
DK3436447T3 (da) Isoquinolinyl-triazolon-komplekser
MA42048A (fr) Dérivés d'aminoesters
MA41641A (fr) Dérivés de tétrahydropyranylbenzamide
DE112017003625A5 (de) Difluorstilben-Derivate
FI20165859A (fi) Runkorakenne
FI11598U1 (fi) Pilkekoneen runkorakenne
IT201600108848A1 (it) Composizioni dermatologiche
DK3303316T3 (da) Ethynylderivater
ES1159608Y (es) Botiquin perfeccionado
ES1148508Y (es) Taburete perfeccionado
ES1157383Y (es) Servilletero perfeccionado